Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Bile Duct Cancer

Bile Duct Cancer

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Bile Duct Cancer

47 trials tracked for Bile Duct Cancer: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 1082 citations.

47Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 35 Phase 1 2 Other / NA 6
  1. Phase 3 Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Completed · 1,082 cited
  2. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Completed · 50 cited
  3. Phase 4 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed
  4. Phase 4 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Completed
  5. Phase 2 Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma Completed
  6. Phase 2 Pembrolizumab and GM-CSF in Biliary Cancer Completed
Show 41 more trials
  1. Phase 2 Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer Completed
  2. Phase 2 A Study of Patients Receiving High-Dose Rate Brachytherapy Completed
  3. Phase 2 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed
  4. Phase 2 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Completed
  5. Phase 2 A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Completed
  6. Phase 2 A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers Completed
  7. Phase 2 Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Completed
  8. Phase 2 Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Completed
  9. Phase 2 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed
  10. Phase 2 A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers Completed
  11. Phase 2 Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Completed
  12. Phase 2 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Completed
  13. Phase 2 A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors Completed
  14. Phase 2 Tremelimumab With Chemoembolization or Ablation for Liver Cancer Completed
  15. Phase 2 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Completed
  16. Phase 2 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Completed
  17. Phase 2 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 Completed
  18. Phase 2 Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer Completed
  19. Phase 2 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma Completed
  20. Phase 2 Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors Completed
  21. Phase 2 CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma Completed
  22. Phase 2 A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors Completed
  23. Phase 2 Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer Completed
  24. Phase 2 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed
  25. Phase 2 Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Completed
  26. Phase 2 Single Agent Regorafenib in Refractory Advanced Biliary Cancers Completed
  27. Phase 2 A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC Completed
  28. Phase 2 My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Completed
  29. Phase 2 Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions Completed
  30. Phase 2 A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Completed
  31. Phase 2 Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Completed
  32. Phase 2 CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery Completed
  33. Phase 2 First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma Completed
  34. Phase 1 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Completed
  35. Phase 1 IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread Completed
  36. N/A Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed
  37. N/A Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) Completed
  38. N/A Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope Completed
  39. N/A Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction Completed
  40. N/A A Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures Completed
  41. N/A A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP Completed

Showing the 47 most-cited and recently-updated of 47 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Bile Duct Cancer: what the trials found

Several interventions have been evaluated in clinical trials for this condition. In studies involving biliary management, the use of a self-expanding metallic stent provided significantly better outcomes compared to plastic stents, including higher rates of adequate biliary drainage (p=0.011 for ITT; p=0.004 for per-protocol) and longer survival times (p=0.0021) 3.

In oncology-focused trials, AG-120 demonstrated a statistically significant improvement in Progression Free Survival (PFS) as determined by independent review (2.7 vs 1.4; p<0.0001) 4. While Cisplatin was evaluated in multiple studies, results regarding Overall Survival (OS) did not reach statistical significance (p=0.41) 5, and a trial reported a radiological response rate of 3% for CR, 7% for PR, and 20% for SD following neoadjuvant therapy 7.

Gemcitabine was associated with a 59.4% rate of patients alive and without progression at 6 months in one cohort compared to 21.2% in another 19. Other established interventions include Pembrolizumab [6, 17], where the latter showed a 0.26 proportion of participants with PFS at 6 months 17, and Cisplatin 22.

Recent results — preliminary, needs further review

  • SHR-1210 is currently being evaluated in Phase 2 trials 1.
  • Zanidatamab (ZW25) showed a Duration of Response (DOR) of 28 patients by ICR and 31 by investigator assessment for DOR ≥ 16 weeks, but these findings are not yet corroborated 10.

For the clinician treating this condition

  • Metallic stents show superior efficacy over plastic stents regarding both drainage adequacy and patient survival 3.
  • AG-120 demonstrated significant improvement in Progression Free Survival (PFS) compared to the control group 4.
  • Gemcitabine showed a higher rate of patients alive and progression-free at 6 months in specific cohorts 19.

AI synthesis of 9 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.